Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)

Quick facts

Marketed products

• Meropenem-Vaborbactam · Infectious Disease
  Meropenem-vaborbactam is a carbapenem antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the carbapenem from enzymatic degradation.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) portfolio CI brief
• Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) pipeline updates RSS